| Assay ID | Title | Year | Journal | Article |
|---|
| AID358719 | Differentiation of MEK1 transfected mouse C2C12 myoblasts into adipocytes at 20 nM assessed under linage-specific inducing condition in absence of drug | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID358698 | Differentiation of human skeletal myoblasts into adipocytes under linage-specific inducing condition at 300 nM after 4 days | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID358705 | Inhibition of cellular apoptosis in presence of 50 uM z-VAD.fmk | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID358695 | Differentiation of mouse C2C12 myoblasts into adipocytes in absence of adipocyte-inducing condition at 20 nM upto 8 days | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID1552047 | Antitumor activity against human COLO205 cells xenografted in mouse assessed as tumor growth inhibition at 150 mg/kg, ip once daily for 4 days relative to control | 2019 | European journal of medicinal chemistry, Aug-01, Volume: 175 | Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A Medicinal chemistry perspective. |
| AID358699 | Differentiation of mouse C2C12 myoblasts into osteoblasts under osteoblast-inducing condition in serum free ITS media at 20 uM | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID1552043 | AUC in mouse xenografted with human HCT116 cells at 30 mg/kg, ip qd | 2019 | European journal of medicinal chemistry, Aug-01, Volume: 175 | Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A Medicinal chemistry perspective. |
| AID358717 | Differentiation of NMMII transfected mouse C2C12 myoblasts into osteoblasts at 20 nM assessed under linage-specific inducing condition in absence of drug | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID358724 | Induction of cell cycle arrest in mouse C2C12 myoblastss assessed as accumulation at G2/M phase at 20 nM after 48 hrs | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID358692 | Differentiation of mouse C2C12 myoblasts into osteoblasts under osteoblast-inducing condition at 20 nM after 48 hrs | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID1203369 | Inhibition of human TTK-mediated MAD1/MAD2 complex phosphorylation after 1 hr by scintillation counting analysis in presence of gamma-[32P]ATP | 2015 | Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
| The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents. |
| AID358700 | Differentiation of mouse C2C12 myoblasts into adipocytes under adipocyte-inducing condition in serum free ITS media at 20 uM | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID1552042 | Cmax in mouse xenografted with human HCT116 cells at 30 mg/kg, ip qd | 2019 | European journal of medicinal chemistry, Aug-01, Volume: 175 | Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A Medicinal chemistry perspective. |
| AID1650705 | Inhibition of recombinant full-length His-tagged human Aurora C expressed in baculovirus expression system | 2020 | Bioorganic & medicinal chemistry letters, 02-01, Volume: 30, Issue:3
| Discovery of novel 2,4-disubstituted pyrimidines as Aurora kinase inhibitors. |
| AID358711 | Inhibition of ATPase activity of myosin 2 in mouse C2C12 myoblast assessed as release of inorganic phosphates | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID358716 | Differentiation of MEK1 transfected mouse C2C12 myoblasts into osteoblasts at 20 nM assessed under linage-specific inducing condition in absence of drug | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID358727 | Differentiation of mouse C2C12 myoblasts into osteoblasts at 10 uM under osteoblast-inducing condition assessed as accumulation at G2M phase | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID358713 | Reversal of ERK2 phosphorylation in mouse C2C12 at 20 uM in presence of 50 uM LY-294002 after 48 hrs | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID358697 | Differentiation of human skeletal myoblasts into osteoblasts under linage-specific inducing condition at 300 nM after 4 days | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID358729 | Differentiation of mouse C2C12 myoblasts into adipocytes at 10 uM under adipocyte-inducing condition assessed as accumulation at S phase | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID358712 | Reversal of ERK1 phosphorylation in mouse C2C12 myoblast at 20 uM in presence of 50 uM LY-294002 after 48 hrs | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID1650704 | Inhibition of recombinant full-length His-tagged human Aurora B expressed in baculovirus expression system | 2020 | Bioorganic & medicinal chemistry letters, 02-01, Volume: 30, Issue:3
| Discovery of novel 2,4-disubstituted pyrimidines as Aurora kinase inhibitors. |
| AID358718 | Differentiation of mock transfected mouse C2C12 myoblasts into osteoblasts at 20 nM assessed under linage-specific inducing condition in absence of drug | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID1552044 | Antitumor activity against human HCT116 cells xenografted in mouse assessed as tumor growth inhibition at 150 mg/kg, ip once daily for 4 days relative to control | 2019 | European journal of medicinal chemistry, Aug-01, Volume: 175 | Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A Medicinal chemistry perspective. |
| AID358706 | Reversal of differentiation of mouse C2C12 myoblasts into osteoblasts under osteoblast-inducing condition at 20 nM in presence of PI3K inhibitor LY-294002 after 48 hrs | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID358708 | Reversal of differentiation of mouse C2C12 myoblasts into osteoblasts under osteoblast-inducing condition at 20 nM after 48 hrs | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID1552041 | Antitumor activity against human HCT116 cells xenografted in mouse assessed as tumor growth inhibition at 30 mg/kg, ip qd relative to control | 2019 | European journal of medicinal chemistry, Aug-01, Volume: 175 | Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A Medicinal chemistry perspective. |
| AID358728 | Differentiation of mouse C2C12 myoblasts into adipocytes at 10 uM under adipocyte-inducing condition assessed as accumulation at G1/S phase | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID671336 | Inhibition of PLK1 | 2012 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
| Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. |
| AID358726 | Differentiation of mouse C2C12 myoblasts into osteoblasts at 10 uM under osteoblast-inducing condition assessed as accumulation at S phase | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID358694 | Differentiation of mouse C2C12 myoblasts into osteoblasts in absence of osteoblast-inducing condition at 20 nM upto 8 days | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID238033 | Antagonist activity against human Adenosine A3 receptor | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
| "Reversine" and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. |
| AID358696 | Differentiation of human 3T3E1 osteoblasts into adipocytes under adipocyte-inducing condition at 300 nM after 4 days | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID358693 | Differentiation of mouse C2C12 myoblasts into adipocytes under adipocyte-inducing condition at 20 nM after 48 hrs | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID358704 | Increase in plasticity in mouse C2C12 myoblasts in presence of 10 ug/mL insulin | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID359559 | Reversal of differentiation of mouse C2C12 myoblasts into adipocytes at 20 nM in presence of trichostatin A after 48 hrs | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID358720 | Differentiation of NMMII transfected mouse C2C12 myoblasts into adipocytes at 20 nM assessed under linage-specific inducing condition in absence of drug | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID358707 | Reversal of differentiation of mouse C2C12 myoblasts into adipocytes under adipocyte-inducing condition at 20 nM in presence of PI3K inhibitor LY-294002 after 48 hrs | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID358721 | Differentiation of mock transfected mouse C2C12 myoblasts into adipocytes at 20 nM assessed under linage-specific inducing condition in absence of drug | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID358723 | Differentiation of mouse C2C12 myoblasts into adipocytes under adipocyte-inducing condition at 10 uM after 48 hrs | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID359558 | Reversal of differentiation of mouse C2C12 myoblasts into osteoblasts at 20 nM in presence of trichostatin A after 48 hrs | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID358730 | Differentiation of mouse C2C12 myoblasts into adipocytes at 10 uM under adipocyte-inducing condition assessed as accumulation at G2/M phase | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID358715 | Inhibition of MEK-dependent ERK2 phosphorylation in mouse C2C12 cells at 20 nM after 1 hr by Western blot | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID358722 | Differentiation of mouse C2C12 myoblasts into osteoblasts under osteoblast-inducing condition at 10 uM after 48 hrs | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID239392 | Percent inhibition of [3H]ZM241,385 binding to human adenosine A2a receptor expressed in CHO cells at 10 uM | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
| "Reversine" and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. |
| AID358725 | Differentiation of mouse C2C12 myoblasts into osteoblasts at 10 uM under osteoblast-inducing condition assessed as accumulation at G1/S phase | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID671331 | Inhibition of Mps1 | 2012 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
| Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. |
| AID239225 | Inhibition of [125I]- AB-MECA binding to human adenosine A3 receptor expressed in CHO cells | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
| "Reversine" and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. |
| AID1552046 | AUC in mouse xenografted with human HCT116 cells at 150 mg/kg, ip once daily for 4 days | 2019 | European journal of medicinal chemistry, Aug-01, Volume: 175 | Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A Medicinal chemistry perspective. |
| AID358703 | Increase in plasticity in mouse C2C12 myoblasts in absence of insulin | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID358689 | Inhibition of myotube formation in mouse C2C12 myoblasts at 20 nM | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID358702 | Differentiation of mouse C2C12 myoblasts into adipocytes under adipocyte-inducing condition in serum containing growth media at 20 uM | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID358701 | Differentiation of mouse C2C12 myoblasts into osteoblasts under osteoblast-inducing condition in serum containing growth media at 20 uM | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID358714 | Inhibition of MEK-dependent ERK1 phosphorylation in mouse C2C12 cells at 20 nM after 1 hr by Western blot | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID239050 | Percent inhibition of [3H]DPCPX binding to human adenosine A1 receptor expressed in CHO cells at 10 uM | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
| "Reversine" and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. |
| AID358691 | Increase in cellular plasticity in mouse C2C12 myoblasts at 20 nM assessed efficiency of adipogenesis under linage-specific inducing condition in absence of drug | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID1650703 | Inhibition of recombinant full-length His-tagged human Aurora A expressed in baculovirus expression system | 2020 | Bioorganic & medicinal chemistry letters, 02-01, Volume: 30, Issue:3
| Discovery of novel 2,4-disubstituted pyrimidines as Aurora kinase inhibitors. |
| AID1552045 | Cmax in mouse xenografted with human HCT116 cells at 150 mg/kg, ip once daily for 4 days | 2019 | European journal of medicinal chemistry, Aug-01, Volume: 175 | Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A Medicinal chemistry perspective. |
| AID358709 | Reversal of differentiation of mouse C2C12 myoblasts into adipocytes under adipocyte-inducing condition at 20 nM after 48 hrs | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID671335 | Inhibition of Aur B | 2012 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
| Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. |
| AID671334 | Inhibition of Aur A | 2012 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
| Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. |
| AID358710 | Inhibition of MEK1 in mouse C2C12 by ERK2 phosphorylation assay | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID358690 | Increase in cellular plasticity in mouse C2C12 myoblasts at 20 nM assessed efficiency of osteogenesis under linage-specific inducing condition in absence of drug | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Jun-19, Volume: 104, Issue:25
| Reversine increases the plasticity of lineage-committed mammalian cells. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347412 | qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID977608 | Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB | 2008 | Molecular cancer therapeutics, May, Volume: 7, Issue:5
| Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |